NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 47.5% and is now trading at $24.89. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.28 by $0.59. The biopharmaceutical company had revenue of $34.03 million for the quarter, compared to the consensus estimate of $59.61 million. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. View Dicerna Pharmaceuticals' earnings history.

11 equities research analysts have issued 12 month price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $34.20 in the next twelve months. This suggests a possible upside of 37.4% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Media headlines about DRNA stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 2,960,000 shares, a drop of 7.8% from the June 15th total of 3,210,000 shares. Based on an average daily trading volume, of 639,600 shares, the days-to-cover ratio is presently 4.6 days. Currently, 4.6% of the shares of the stock are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), PPD (SDGR), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $24.89.

Dicerna Pharmaceuticals has a market capitalization of $1.84 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]